Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Paxil Authorized Generic: Par Gets Puerto Rico Now, States Later

Executive Summary

Par and Pentech will be entitled to launch an "authorized" generic version of GlaxoSmithKline's Paxil on U.S. mainland once another generic is launched, under the companies' patent litigation settlement

You may also be interested in...



GSK/Par Paxil Generic Deal Upheld In Court; FTC Closes Patent Investigation

GlaxoSmithKline's "authorized" generic Paxil agreement with Par does not raise any antitrust concerns, Chicago federal court Judge Richard Posner ruled Oct. 29

GSK/Par Paxil Generic Deal Upheld In Court; FTC Closes Patent Investigation

GlaxoSmithKline's "authorized" generic Paxil agreement with Par does not raise any antitrust concerns, Chicago federal court Judge Richard Posner ruled Oct. 29

Apotex Generic Paxil Priced At 7% Discount Following “At Risk” Launch

Apotex is relying on a district court ruling of noninfringement in launching the first generic of GlaxoSmithKline's antidepressant Paxil (paroxetine)

Related Content

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel